EndoTODAY | EndoATLAS | ¿Ü·¡¼³¸íÀÚ·á

±â»ýÃæ | ½Äµµ | À§ | À§¾Ï | ESD | õ±â´©¼³

Home | Guide | ÁÖÀÎÀå | ±¸µ¶ | °Ë»ö | ¸µÅ©


[2015 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ Ãß°è Çмú´ëȸ]

¾Æħ 8½ÃºÎÅÍ ´ÊÀº ¿ÀÈıîÁö ¸¹Àº ¹ßÇ¥°¡ ÀÖ¾ú½À´Ï´Ù. ¸¶Áö¸· ¹ßÇ¥°¡ ³¡³¯ ¶§±îÁö ÀÚ¸®¸¦ ÁöÅ°¸ç È°¹ßÈ÷ ÁúÀÇ ÀÀ´äÀ» ÇØ ÁֽŠ¿©·¯ ¼±»ý´Ôµé²² °¨»çÀÇ ¶æÀ» ÀüÇÕ´Ï´Ù. °³ÀÎÀûÀ¸·Î´Â 6³â°£ °è¼ÓµÇ¾ú´ø ¼ÒÈ­±âÇÐȸ ÇмúÀ§¿ø »ýÈ°ÀÌ ¿À´Ã ³¡³µ½À´Ï´Ù. ´ÙÀ½ ´ÞºÎÅÍ´Â ³»½Ã°æÇÐȸ ÇмúÆÀÀåÀ¸·Î »ì¾Æ°¥ ¿¹Á¤ÀÔ´Ï´Ù.

1¹ø¹æ ¸¶Áö¸· ±¸¿¬ÀÌ ÀÖ¾ú´ø ¿ÀÈÄ 4½Ã 20ºÐ¿¡ ÃÔ¿µÇß½À´Ï´Ù.


1. Risk management for infectious disease in endoscopy unit - ¼º±Õ°üÀÇ´ë ÀÌÁØÇà

ÃÔ¿µ: ¹®Á¤¼·

¸Þ¸£½º·Î ÀÎÇØ ¾î¼ö¼±Çß´ø 2015³âµµ ÀÌÁ¦ Àú¹°¾î°¡°í ÀÖ½À´Ï´Ù. ±× ¶§¹®ÀÎÁö ¾îÁ¦ ¼ÒÈ­±âÇÐȸ¿¡¼­µµ '¿À·¡µÈ °¨¿°º´°ú »õ·Î¿î °¨¿°º´'À̶õ Á¦¸ñÀÇ °¨¿°º´ ½ÉÆ÷Áö¾öÀÌ ÀÖ¾ú½À´Ï´Ù. ±â»ýÃæÁúȯ, Ebola º´, ¸Þ¸£½º¿¡ ´ëÇÏ¿© »ý°¢Çغ¸´Â ½Ã°£À̾ú´Âµ¥¿ä, ÁÂÀåÀ̴̼ø ¼­¿ï´ëÇб³ ¿À¸íµ· ±³¼ö´Ô²²¼­ ²À ÀüÇØ´Þ¶ó´Â ¸»¾¸ÀÌ ÀÖ¾ú½À´Ï´Ù. ¿Å±â°Ú½À´Ï´Ù.

"Ebola º´Àº ¾ÆÇÁ¸®Ä« ÀÚÀÌ·¹¿¡ ÀÖ´ø ÇÑ º´¿øÀÇ ¼­¾ç °£È£»çµéÀÌ ÅäÂøº´À¸·Î »ç¸ÁÇϸ鼭 ¾Ë·ÁÁö°Ô µÇ¾ú½À´Ï´Ù. °¨¿°º´ Ãʱâ, ƯÈ÷ ½ÅÁ¾ °¨¿°º´ Ãʱ⿡´Â ȯÀÚ°¡ Áø´ÜµÇÁö ¾ÊÀº »óÅ¿¡¼­ °Ë»ç ¹× Ä¡·á¸¦ ¹Þ°Ô µË´Ï´Ù. ÀÌ °úÁ¤¿¡¼­ ÀÇ·áÁø °¨¿°ÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. À̹ø ¸Þ¸£½º »çÅ¿¡¼­ °¨¿°µÈ ȯÀÚÀÇ 20%°¡ ÀÇ·áÁøÀ̾ú½À´Ï´Ù. °¨¿°º´Àº ȯÀÚ¸¸ÀÇ ÀÏÀÌ ¾Æ´Õ´Ï´Ù. ÀÇ·áÁøÀÇ ¹®Á¦À̱⵵ ÇÕ´Ï´Ù. ±×·±µ¥ °¡Àå À§ÇèÇÑ °÷ Áß Çϳª°¡ ³»½Ã°æ½ÇÀÔ´Ï´Ù. Áø´ÜµÇÁö ¸øÇÑ Áúº´¿¡ ÀÇÇØ ³»½Ã°æ Àǻ簡 °¨¿°µÉ À§Ç輺Àº ¾ÆÁÖ ³ô½À´Ï´Ù. Universal precautionÀÌ Áß¿äÇÕ´Ï´Ù. ¸Å¿ì ÁÖÀÇÇØ¾ß ÇÑ´Ù°í »ý°¢ÇÕ´Ï´Ù."

Áö³­ ¸Þ¸£½º »çÅ µ¿¾È Àú´Â »ï¼º¼­¿ïº´¿øÀÇ ¹æ¿ªÆÀÀåÀ¸·Î ÀÓ¸íµÇ¾î ÀûÁö ¾ÊÀº °í»ýÀ» ÇÏ¿´½À´Ï´Ù. ¸Þ¸£½º ȯÀÚ µÚ¸¦ µû¶ó ´Ù´Ï¸é¼­ ȯ°æ¼Òµ¶À» ÇÏ´Â °ÍÀÌ ÁÖµÈ ÀÓ¹«¿´½À´Ï´Ù. ¾Æ¿ï·¯ ³»½Ã°æ½ÇÀåÀ̱⵵ ÇÏ¿´À¸¹Ç·Î, ¸Þ¸£½º ȯÀÚ¿Í °Ý¸® ´ë»óÀÚÀÇ ³»½Ã°æ °Ë»ç¿Í °ü·ÃµÈ ½Ç¹«ÀûÀÎ °í¹Îµµ ÇÏ¿´½À´Ï´Ù. ÀÌ·± Àú·± °æÇèÀ» ÅëÇÏ¿© »ó´çÈ÷ ¸¹Àº °ÍÀ» ¾Ë°Ô µÇ¾ú½À´Ï´Ù. ±×·±µ¥ ÀÌ»óÇÑ ÀÏÀÌ ÀÖ¾ú½À´Ï´Ù. ¸Þ¸£½º »çÅ°¡ ³¡³­ ÈÄ ¾Æ¹«µµ ã¾Æ¿À´Â »ç¶÷ÀÌ ¾ø¾ú´Ù´Â °ÍÀÔ´Ï´Ù.

¿ì¸® ¸ðµÎ Àß ¾Ë°í ÀÖ½À´Ï´Ù. ¸Þ¸£½º´Â ´Ù½Ã µ¹¾Æ¿É´Ï´Ù. Áßµ¿°úÀÇ ±³·ù°¡ È°¹ßÇϱ⠶§¹®ÀÔ´Ï´Ù. ¶Ç ´Ù¸¥ ½ÅÁ¾ °¨¿°º´ À§Çèµµ ´Ã Á¸ÀçÇÕ´Ï´Ù. »çÀü¿¡ öÀúÈ÷ ÁغñÇÏ´Â ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. Áö³­ ¸Þ¸£½º ±â°£ µ¿¾È ÀúÈñ º´¿ø ÀÇ»çµéÀÌ ¾î¶² ½Ç¹«Àû °æÇèÀ» ÇÏ¿´´ÂÁö µé¾îº¸´Â °ÍÀº ½ÅÁ¾ °¨¿°º´ ´ëºñÀÇ Áß¿äÇÑ Ãâ¹ßÁ¡ÀÏ °ÍÀ¸·Î »ý°¢ÇÕ´Ï´Ù. ¿©·¯ºÐÀº ¸Þ¸£½º ȯÀÚ°¡ ³»½Ã°æ½Ç·Î ã¾Æ¿ÔÀ» ¶§ ¾î¶»°Ô °Ë»çÇØ¾ß ÇÏ´ÂÁö Àß ¾Ë°í °è½Ê´Ï±î?

Àú´Â À̾߱âÇÏ°í ½Í¾ú´Âµ¥ ¾Æ¹«µµ ºÒ·¯ÁÖ´Â »ç¶÷ÀÌ ¾ø¾ú½À´Ï´Ù. ´ä´äÇÏ´ø Áß ¸¶Ä§ ³»½Ã°æ ÇÐȸ¿¡¼­ '³»½Ã°æ½ÇÀÇ °¨¿°°ü¸®'¿¡ ´ëÇÏ¿© ¹ßÇ¥ÇÒ ±âȸ¸¦ Áּ̽À´Ï´Ù. °¨»çÇÕ´Ï´Ù. ¿À´Ã Àú´Â ³»½Ã°æ½Ç °¨¿°¿¡ ´õÇÏ¿© ¸Þ¸£½º À̾߱⸦ Á¶±Ý Çغ¸·Á°í ÇÕ´Ï´Ù. ½Ã°£ÀÌ Âª°í °ø°³µÈ Àå¼ÒÀÎÁö¶ó ¸ðµç À̾߱⸦ ´Ù ÇÒ ¼ö´Â ¾ø½À´Ï´Ù. ±Ã±ÝÇÑ Á¡ÀÌ ÀÖÀ¸½Å ºÐÀº ¾ðÁ¦µçÁö ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù. °­ÀÇ ½ÃÀÛÇÏ°Ú½À´Ï´Ù.


2. »óºÎÀ§Àå°ü ½ÉÆ÷Áö¾ö

1) Anticoagulation and endoscopy. ÇѸ²´ëº´¿ø ½Å¿î°Ç

NOACÀÇ ´ÜÁ¡Àº Çص¶Á¦°¡ ¾ø´Ù´Â Á¡ÀÔ´Ï´Ù (´Ü 2015³â¿¡ ¹Ì±¹ FDA¿¡¼­ idarucizumab (Praxbind)°¡ dabigatran reversal agent·Î Çã°¡¹Þ¾Ò½À´Ï´Ù).

RibaroxabanÀº warfarin ´ëºñ ÃâÇ÷·üÀÌ ³ô½À´Ï´Ù. Dabigatranµµ major GI bleedingÀÌ Á¶±Ý ¸¹½À´Ï´Ù.

* Âü°í: EndoTODAY ³»½Ã°æ Àü Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦¸¦ ²÷À» °ÍÀΰ¡?


2) Non-variceal upper GI bleeding. °æÈñ´ëÇб³ ÀåÀ翵

Epinephrine ´Üµ¶ injection ¿ä¹ýÀº ±Ç°íµÇÁö ¾Ê½À´Ï´Ù.

Second look endoscopy´Â ´õ ÀÌ»ó ±Ç°íµÇÁö ¾Ê°í ÀÖÁö¸¸, ¾ÆÁ÷ ¸¹Àº ÀÇ»çµéÀÌ second look endoscopy¸¦ ÇÏ°í °è½Ê´Ï´Ù. ÀåÀ翵 ±³¼ö´Ôµµ ´ëºÎºÐ second look endoscopy¸¦ ÇÏ°í ÀÖ´Ù°í ¸»¾¸Çϼ̽À´Ï´Ù.

¿À´Ã °­ÀÇ¿¡¼­ ¼Ò°³µÇÁö ¾Ê¾ÒÁö¸¸, EndoscopyÁö 2015³â 8¿ùÈ£¿¡ °æÈñ´ë ÀåÀ翵 ±³¼ö´ÔÆÀÀÇ ÈǸ¢ÇÑ ¿¬±¸°á°ú°¡ ¼Ò°³µÇ¾ú½À´Ï´Ù. ÃâÇ÷¼º ¼ÒÈ­¼º±Ë¾ç¿¡¼­ Coagrasper¿¡ Soft coagulation Àü·ù¸¦ Åë°ú½ÃÄÑ ÁöÇ÷ÇÑ °Í°ú APC·Î ÁöÇ÷ÇÑ °ÍÀÇ È¿°ú°¡ ºñ½ÁÇÏ´Ù´Â °á·ÐÀ̾ú½À´Ï´Ù. ¿¬±¸ ¹æ¹ý¿¡ ¼±»ý´ÔÀÇ ºñ¹ýÀÌ Àß Á¤¸®µÇ¾î ÀÖ½À´Ï´Ù.

* Âü°í: EndoTODAY ¼ÒÈ­¼º ±Ë¾ç ÃâÇ÷


3) Bariatric endoscopic treatment. ¿¬¼¼´ëÇб³ ½Å¼º°ü

ºñ¸¸Àº º¸±â ½ÈÀº »óÅ°¡ ¾Æ´Ï¶ó Áúº´ÀÔ´Ï´Ù. ¼­¾çÀο¡ ºñÇÏ¿© µ¿¾çÀο¡¼­´Â µ¿ÀÏ BMI¿¡¼­ üÁö¹æ·üÀÌ ³ô°í ºñ¸¸°ü·Ã Áúȯµµ ¸¹±â ¶§¹®¿¡ ¼­¾çº¸´Ù ´Ù¼Ò tightÇÑ Áø´Ü±âÁØÀ» Àû¿ëÇØ¾ß ÇÕ´Ï´Ù.

ºñ¸¸ °ü·ÃÇÏ¿© À§¸¦ ¼ö¼úÇϸé üÁß°¨¼ÒÈ¿°ú¸¸ ÀÖÁö¸¸ ¼ÒÀåÀ» ¼ö¼úÇϸé üÁßÀÌ ºüÁú»Ó¸¸ ¾Æ´Ï¶ó ´ç´¢°ü·Ã ¿©·¯ ÁöÇ¥°¡ °³¼±µË´Ï´Ù. ¾ÆÁ÷±îÁö Àß ¾Ë·ÁÁöÁö ¾ÊÀº ±âÁØÀÌ ÀÖÀ» °ÍÀÔ´Ï´Ù. üÁß°¨¼Ò ½Ã¼ú ÈÄ ´ç´¢°¡ ÁÁ¾ÆÁö´Â ±âÀü Áß Çϳª·Î incretin À̶ó´Â È£¸£¸óÀÇ ¿ªÇÒÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¿¹»óÄ¡ ¸øÇÑ ´Ù¸¥ ±âÀüµéµµ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

´ëÇÑÀÓ»ó¼ÒÈ­±â³»°ú 2015;2(3)

1) À§¿¡ ½Ã¼úÇÏ´Â ¹æ¹ý

(1) Apollo overstich¸¦ ÀÌ¿ëÇÑ sleeve gastrectomy

(2) Incisionless operating plateform

(3) Aspiration therapy: PEG¿Í ºñ½ÁÇÑ ¿ø¸®·Î À½½ÄÀ» ¸Ô°í PEG tube¸¦ ÅëÇØ À½½ÄÀ» »Ì¾Æ³»´Â ¹æ¹ý.

2) ¼ÒÀå¿¡ ½Ã¼úÇÏ´Â ¹æ¹ý

(1) Duodenal sleeve

(2) Duodenal mucosal resurfacing


3. Selected presentations

UGI-1. ¿¬¼¼ÀÇ´ë Cheal Wung Huh. Gastric carcinoma with lymphoid stroma (GCLS)

41(1.2%) patients were diagnosed as GCLS among EGC. When compared between GCLS and P/D, the LNM rate was significantly lower in GCLS than PD after adjustment of depth of invasion.

±èÁöÇö ¼±»ý´ÔÀº GCLS¸¦ ³»½Ã°æ ÀýÁ¦¼ú Àü¿¡ Áø´ÜÇϱ⠾î·ÆÁö¸¸, ESD pathology¿¡¼­ GCLS·Î ³ª¿À¸é Ãß°¡ ¼ö¼ú ¿©ºÎ¸¦ °áÁ¤ÇÒ ¶§ À̹ø ÀÚ·á°¡ µµ¿òÀÌ µÉ °ÍÀ̶ó°í ¼³¸íÇϼ̽À´Ï´Ù.

UGI-2. ºÎõ¼øõÇâ. Hyung Min Noh. Á¶Á÷°Ë»ç¿¡¼­ atypical epitheliumÀ¸·Î ³ª¿Â 723¿¹ Áß 147¿¹¸¦ ³»½Ã°æÀýÁ¦ÇÏ¿´À» ¶§, 76.2%´Â ¾ÏÀ̾ú½À´Ï´Ù.

UGI-3. ÀÎõ¼º¸ðº´¿ø. Sung Min Park. Agreement of ulcer in EGC among endoscopists

º» ¿¬±¸¿¡¼­ ulcerationÀº 'ulcer + ulcer scar'·Î Á¤ÀÇÇÏ¿´½À´Ï´Ù.

¾Ö¸ÅÇÑ °æ¿ì´Â ESD °æÇèÀÌ ¾ø´Â Àǻ簡 ulcerationÀ¸·Î ÆÇÁ¤ÇÏ´Â °æ¿ì°¡ ¸¹¾Ò½À´Ï´Ù.

UGI-4. ¼­¿ï¾Æ»êº´¿ø. Sunpyo Lee. Extragastric recurrence

Absolute indication 2391¸í¿¡¼­´Â extragastric recurrence°¡ ¾ø¾ú½À´Ï´Ù.

Expanded indication 1422¸í¿¡¼­´Â 0.28%ÀÎ 4¸í¿¡¼­ extragastric recurrence°¡ ÀÖ¾ú½À´Ï´Ù. ¸ðµÎ regional node Àç¹ßÀ̾ú½À´Ï´Ù.

Beyond expanded indication 297¸íÀÇ 5¸í¿¡¼­ extragastric recurrecne°¡ ÀÖ¾ú½À´Ï´Ù. 3¸íÀº regional node, 2¸íÀº distant metastasis¿´½À´Ï´Ù.

UGI-5. ¼­¿ï¾Æ»êº´¿ø. Eun Jeong Gong. Usefulness of repetitive endoscopic evaluation before ER

Á¤ÈÆ¿ë ±³¼ö´Ô²²¼­´Â ESD¸¦ À§ÇØ ÀÇ·ÚµÈ È¯ÀÚ¿¡¼­ ´çÀÏ EGD¿Í EUS¸¦ ÇÏ°í °è½Å´Ù°í ¼³¸íÇϼ̽À´Ï´Ù. Àú´Â ¾à 90%¿¡¼­ ESD Àü ³»½Ã°æ Àç°Ë ¾øÀÌ ½Ã¼úÇÏ°í ÀÖ´Ù°í comment ÇÏ¿´½À´Ï´Ù (»ï¼º¼­¿ïº´¿øÀÇ policy´Â ¾Æ´Ï°í ÀúÀÇ °³ÀÎ policyÀÔ´Ï´Ù. Àç°ËÇÏ´Â ±³¼ö´Ôµµ °è½Ê´Ï´Ù). ÁÂÀå´Ô²²¼­´Â º´¼Ò°¡ 2°³¸é ÇѲ¨¹ø¿¡ ½Ã¼úÇÏ´ÂÁö Áú¹®ÇÏ¼Ì°í ¹ßÇ¥ÀÚ´Â ±×·¸´Ù°í ´äÇÏ¿´½À´Ï´Ù. Àúµµ 2°³ º´¼Ò´Â ´ëºÎºÐ ÇѲ¨¹ø¿¡ ½Ã¼úÇÏ°í ÀÖ½À´Ï´Ù. Çϳª´Â 100%, ´Ù¸¥ Çϳª´Â 50%·Î û±¸ÇÏ°í ÀÖ½À´Ï´Ù. Áï ESD¸¦ µÎ °³ Çϸé Çϳª´Â ½Ã¼ú·á¸¦ 100% ¹ÞÀ» ¼ö ÀÖ°í, ´Ù¸¥ Çϳª´Â 50%¹Û¿¡ ¹ÞÁö ¸øÇÕ´Ï´Ù.

UGI-21. ¼­¿ï¾Æ»êº´¿ø. ¾ÈÁö¿ë. Tissue effect of APC on human gastric mucosa

To completely remove submucosal layer without injuring proper muscle layer, 800 Joule was needed in non-injection group, however, in normal salineinjection group, there was noproper muscle damage until 2000 Joule was applied by APC.

After saline injection, more 800 Joule of energy is needed to ablate complete mucosal layer. Without saline injection, more than 900 Joule of energy can make proper muscle damage.

UGI-22. °æºÏ´ëÇб³. Àü¼º¿ì. New endoscopic knife (O type knife)

Acute bleeding rate (moderte to severe grade) occurred during the procedure was significant lower in O group (10% vs 35%, p = 0.031)

UGI-23. ¿¬¼¼´ëÇб³. ±èÇöÁÖ. Adenocarcinoma of EG junction (Siewart type II)

During follow-up, recurrence occurred only ESD groups (6/38 vs 0/28, p = 0.035). Surgery-related death occurred in the surgery group (1/28).

[Âü°í] µé¹®ºÎ À§¾Ï°ú ¹Ù·¿½Äµµ¾ÏÀÌ ¼¯¿©ÀÖÀ» °Í °°¾Æ¼­ Áú¹®À» Çß½À´Ï´Ù. ±×·±µ¥ ÀÇ¿Ü·Î ¸ðµÎ µé¹®¾ÏÀ̾ú´Ù°í ÇÕ´Ï´Ù. ¹Ù·¿½Äµµ¾ÏÀÌ ¾ø¾ú´Ù´Â Á¡¿¡¼­ ´Ù¼Ò ÀÇ¿Ü¿´½À´Ï´Ù.

UGI-43. °æºÏ´ëÇб³. Dong Gun Kim. »óºÎÀ§Àå°ü ÃâÇ÷¿¡¼­ ³»½Ã°æ ½ÃÁ¡

Late endoscopy (>24 hours) is sufficient for management of NVUGIB in the low risk patients. Urgent endoscopy (< 6 hours) reduced co-morbidity aggravation in the high risk group.

UGI-50. ¿¬¼¼´ëÇб³. Hyunsoo Chung. POEM

26 patients (24 achlasia, 2 DES)
Mean operating time: 81 (47-132) minutes.
Oral intake: postoperative day 1
Length of hospital stay: 5 days.
Eckardt score: pre-POEM: 7 → post-POEM 0.7
Clinical success rate (Eckardt score <= 3): 96.1%

UGI-61. ¼­¿ï¾Æ»êº´¿ø. Easy-to-manufacture training simulator for endoscopic biopsy of the stomach

³»½Ã°æ Á¶Á÷°Ë»ç¸¦ À§ÇÑ endoscopic biopsy simulator¸¦ °³¹ßÇÏ¿© Æò°¡ÇÑ ¿¬±¸ÀÔ´Ï´Ù. ÀÌÁøÇõ ¼±»ý´ÔÀÇ ÈǸ¢ÇÑ ideaÀÎ °Í °°½À´Ï´Ù.


5. Selected cases (poster)

1) Àü³²´ëÇб³. A case of syphilitic gastritis mimicking AGC


[ÀÌÁØÇà comment] ÃÖ±Ù À§¸Åµ¶ gastric syphilisÀÌ Á¶±Ý¾¿ Áõ°¡ÇÏ°í ÀÖ´Â µí ÇÕ´Ï´Ù. ÀüüÀûÀ¸·Î ¸Åµ¶ÀÌ Áõ°¡ÇÏ°í ÀÖÀ¸¹Ç·Î À§¸Åµ¶µµ µû¶ó¼­ Áõ°¡ÇÏ´Â ¸ð¾çÀÔ´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼­ ¸Åµ¶ ȯÀÚ´Â »ý°¢º¸´Ù ¸¹½À´Ï´Ù. 2008³âÀÇ °æ¿ì 1,548¸íÀ̾ú´Ù°í ÇÕ´Ï´Ù (Clin Endosc 2015;48:256). AIDS ¶§¹®¿¡ ´Ù¸¥ ¼ºº´ÀÌ ¹«½ÃµÇ°í Àֱ⠶§¹®ÀÎ °ÍÀ¸·Î ÃßÁ¤ÇÏ°í ÀÖ½À´Ï´Ù. Gastric syphilisÀÇ Æ¯Â¡À» Á¤¸®ÇÏ¸é ¾Æ·¡¿Í °°½À´Ï´Ù.
1. Secondary and tertiary stage
2. Incidence in syphilis; <1%
3. Endoscopy; erosive gastritis or gastric ulcer with heaped, nodular edges or thickened, edematous rugal folds.
4. Histopathologic findings; suggestive, but not diagnostic
Á¦°¡ Áö±Ý±îÁö ¾Ë°í ÀÖ´Â gastric syphilis 6¿¹ÀÇ »çÁøÀÔ´Ï´Ù. ƯÈ÷ ù¹ø° Áõ·Ê°¡ º¸¸¸ 4Çü ÁøÇ༺ À§¾Ï°ú ºñ½ÁÇß½À´Ï´Ù.


2) °­¿ø´ëÇб³. Eosinophilic gastritis associated with cerebral sparganosis

3) IS ÇѸ²º´¿ø. Acute esophageal necrosis associated with acute pyelonephritis

4) ÇѸ²º´¿ø. Small cell carcinoma of esophagus with multiple hepatic metastasis

5) ºÎ»ê´ëº´¿ø. Solitary Langerhans cell histocytosis of the stomach treated by ESD

6) ÇѾç´ëÇб³. Acute esophageal necrosis

7) Á¶¼±´ëÇб³. Metachronous rectal metastasis from AGC


6. °­ºÏ»ï¼ºº´¿ø, â¿ø»ï¼ºº´¿ø, »ï¼º¼­¿ïº´¿ø ÇÕµ¿ Áý´ãȸ

1) °­ºÏ»ï¼ºº´¿ø Áõ·Ê - ô¼ö½Å°æÁúȯ¿¡ ÀÇÇÑ º¹Åë

º¹ºÎ CT¿¡¼­´Â ƯÀ̼ҰßÀÌ ¾ø¾ú°í MRI¿¡¼­ T-spine cystic tumor°¡ ¹ß°ßµÇ¾î ¼ö¼úÇÔ.


2) â¿ø»ï¼ºº´¿ø Áõ·Ê - CBD stone ¿ÀÀÎÇÏ¿´´ø cystic artery aneurysm (´ã³¶°¡¼ºµ¿¸Æ·ù)

PTBD ¹× PTGBD ½ÃÇà → hematemesis·Î EGD ½ÃÇàÇÏ¿´°í ampulla of Vater¿¡¼­ blood oozingÀÌ ÀÖ¾úÀ½. → GB bed¿¡¼­ aneurysm ÀÖ¾î embolization ½ÃÇà. → Laparoscopic cholecystectomy ½ÃÇà. GB empyema ¿´À½.


3) »ï¼º¼­¿ïº´¿ø Áõ·Ê

ôÃß ³ó¾çÀ¸·Î ³»¿øÇÏ¿´´ø sparganum Áõ·Ê¸¦ ¼Ò°³ÇÏ¿´½À´Ï´Ù. 50´ë ³²¼ºÀÌ "´Ù¸®¿¡ ÈûÀÌ ¾ø°í °ÉÀ» ¶§ ÈÖû°Å¸°´Ù"´Â Áõ»óÀ¸·Î ³»¿øÇϼ̽À´Ï´Ù. Spine MRI¿¡¼­ T2-4 epidural abscess°¡ ÀǽɵǾî ÇØ´çºÎÀ§ ôÃ߸¦ hemilaminectomy ÇÏ¿´½À´Ï´Ù (¹°·Ð Á¦°¡ ÇÑ °ÍÀº ¾Æ´Õ´Ï´Ù^^). ¾à 15 cmÀÇ È¸Ãæºñ½ÁÇÑ °ÍÀÌ ³ª¿Ô´Âµ¥, È®ÀÎÇØ º» ¹Ù SparganumÀ̾ú½À´Ï´Ù.

½ºÆĸ£°¡´®ÁõÀº ¸¸¼Õ¿­µÎÁ¶ÃæÀÇ plerocercoid À¯ÃæÀÇ ÀÎü °¨¿°º´À¸·Î ¼¼°èÀûÀ¸·Î ºÐÆ÷ÇÕ´Ï´Ù. Áß°£¼÷ÁÖÀÎ ¹ì, °³±¸¸® µîÀ» ºÒÃæºÐÇÏ°Ô ÀÍÇô ¸ÔÀ» ¶§ °¨¿°µË´Ï´Ù. ¿ì¸®³ª¶ó´Â ÀÎü½ºÆĸ£°¡´®ÁõÀÇ ³óÈÄÇÑ À¯ÇàÁö·Î¼­ ¼¼°èÀûÀ¸·Î Áõ·Ê°¡ °¡Àå ¸¹´Ù°í ÇÕ´Ï´Ù. ½ºÆĸ£°¡´® À¯Ãæ (plerocercoid) ÀÚü´Â Èò»ö ¶Ç´Â Ȳ»ö ¸®º» ¸ð¾çÀÇ ±ÙÀ°Áú À¯ÃæÀÔ´Ï´Ù. ±æÀÌ´Â 5-20cm Á¤µµÀÌ°í ½ÅÃ༺ÀÌ ÁÁ¾Æ ¼ö½Ê cm·Î ±æ°Ô ´Ã¾î³¯ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ·Î 20-30´ë ³²ÀÚ°¡ ¹ìÀ» ¸Ô¾î¼­ °¨¿°µË´Ï´Ù. Àü±¹ÀÇ ¹ì¿¡¼­ ½ºÆĸ£°¡´®ÀÌ °ËÃâµÇ°í ÀÖ½À´Ï´Ù. Áõ·ÊÀÇ 20%´Â ¿©ÀÚÀε¥ À̵éÀº °ú°Å·Â»ó ¹ìÀ̳ª °³±¸¸®¸¦ ¸ÔÀº ÀÏÀÌ ¾ø´Â °æ¿ì°¡ ¸¹¾Æ À½·á¼ö¿¡ ÀÇÇÑ °¨¿°À¸·Î ÃßÁ¤µË´Ï´Ù. ÀÎü ½ºÆĸ£°¡´®ÁõÀÇ °æ¿ì Ãæü°¡ ÇÇÇÏ¿¡¼­ À̵¿ÇÕ´Ï´Ù. º¹º®, À½³¶, ÇÏÁö, È亮 µî¿¡ ÈçÇÏ°Ô Ä§ÀÔÇϸç, ¿©¼ºÀÇ °æ¿ì À¯¹æ¿¡ ÈçÈ÷ ħ¹üÇÑ´Ù. º¹°­, Èä°­, ô¼ö, ¾È±¸ ÁÖÀ§, ³ú µî¿¡µµ ħÀÔÀÌ °¡´ÉÇÏ´Ù. ô¼ö °¨¿°½Ã ÇϹݽŠ¸¶ºñ¸¦ À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿Ü°úÀû ÀûÃâ¼úÀÌ À¯ÀÏÇÑ Ä¡·á¹ýÀ̸ç È¿°úÀûÀÎ ¾àÁ¦´Â ¾ø½À´Ï´Ù.

Inguinal area¿Í thigh¿¡¼­ sparganumÀ» Á¦°ÅÇÏ´Â ¸ð½À´Ï´Ù.

ÀúÈñ º´¿ø ȯÀÚ¿Í ¸Å¿ì ºñ½ÁÇÑ Áõ·Ê¸¦ ÀÎÅͳݿ¡¼­ ¹ß°ßÇÏ¿´½À´Ï´Ù. SpineÀÇ SparganumÀÔ´Ï´Ù.


[Âü°íÀÚ·á]

1) ³»½Ã°æÇÐȸ ÇмúÇà»ç on-line Áß°è

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà